Synchronization Technologies, a leader in brain-computer interface (BCI) technology, has secured a substantial $200 million in Series D funding. The financing round is led by CEO Thomas Oxley, marking an exciting step forward for the company’s expansion efforts, particularly in New York. ‘$200 Million Funding Round Boosts BCI Leap,’ This funding will support Synchron’s development of its revolutionary Stentrode device. It has been confirmed that the company plans to significantly increase operations and commercialize their groundbreaking technology. The funding round is notable not only for its size but also for the participation of global investors, indicating a strong belief in Synchron’s mission to improve communication for individuals with paralysis.